Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy

17 May 2018

Abstract excerpt

Aims: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapy to treat hypercholesterolaemia and related cardiovascular diseases. This study determined if PCSK9 can regulate infarct size, cardiac function, and autophagy during ischaemia. Methods and results: Mice hearts were subjected to left coronary artery (LCA) occlusion. There was intense expression of PCSK9 in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cardiac Fibrosis and Remodeling
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29800228
DOI: 10.1093/cvr/cvy128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagyPMID 29800228Read ↗

PCSK9 inhibition in myeloid cells enhances cardioprotection beyond its LDL cholesterol-lowering effectsSemantic proximity Read ↗

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read ↗

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.Semantic proximity Read ↗

PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagySemantic proximity Read ↗

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement.Semantic proximity Read ↗

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read ↗

PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expressionSemantic proximity Read ↗

PCSK9 affects expression of key surface proteins in human pancreatic beta cells through intra- and extracellular regulatory circuitsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.